txb-103
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02737748)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Molecular identity unknownImmunity, passive
Molecular identity unknown immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- txb-103
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02737748 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | A2 Healthcare Taiwan Corporation, Government of Taiwan, Transwell Biotech Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| A2 Healthcare Taiwan Corporation | For profit | 1 | 0 | 1 | 2016 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2016 |
| Transwell Biotech Co., Ltd. | For profit | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1